Check out your Company Bowl for anonymous work chats.
NVIDIA Spotlights Digital Diagnostics as AI Healthcare Pioneer at GTC 2025
With rapid adoption and scalability, LumineticsCore is revolutionizing healthcare by improving outcomes, advancing health equity, reducing costs, and enhancing physician satisfaction and productivity. Discover how getting AI right from the start is reshaping the future of healthcare.
Discover what the LumineticsCore™ AI diagnostic experience is like from two people living with diabetes. Learn how LumineticsCore plays a pivotal role in diagnosing diabetic retinopathy at the point-of-care, simplifying diabetes management, and streamlining the eye exam for diabetes.
Digital Diagnostics Mission: Transforming Global Healthcare with AI
Orbis International, Digital Diagnostics, and Deep Eye Care Foundation, Bangladesh, announce new findings demonstrating autonomous AI significantly improves the productivity of medical caregivers testing for diabetic eye disease by 40%. The peer-reviewed randomized controlled trial study, published in Nature, is the first to explore how autonomous AI can enhance the productivity of healthcare professionals globally, allowing them to see more patients while prioritizing those who require their care and expertise. This study, which was conducted in Bangladesh, demonstrates the potential for autonomous AI to increase access to essential services and reduce health inequities, including in low and middle-income countries with shortages of trained specialists.
The most recent Digital Diagnostics’ Hackathon brought together employees from the Engineering, Machine Learning, Product, and Customer Success teams for two days of cross-collaboration, innovation, and team-bonding activities.
Digital Diagnostics, a leading artificial intelligence diagnostic health care company, announced its expansion into lab settings in the southeast region of the United States. The company’s flagship product, LumineticsCore™ formerly IDx-DR, is now available in nine Labcorp patient service centers (PSCs) in Alabama providing access to care for people with diabetes through the initial market launch of the De Novo FDA-cleared autonomous artificial intelligence diagnostic system.
Digital Diagnostics – a leading AI diagnostics company on a mission to transform global healthcare – is a recipient of CB Insights’ fourth-annual Digital Health 150. The list recognizes the 150 most promising private digital health companies of 2022.
Digital Diagnostics’ Co-Founder, COO and President, spoke with top leadership speaker Adam Mendler about thought leadership, business advice and tips for entrepreneurs, including how to lead with speed and grace. You can read the full interview on the Adam Mendler blog.
Digital Diagnostics – a leading AI diagnostics company on a mission to transform global healthcare – has rebranded its flagship product, the AI diagnostic system formerly known as IDx-DR, to LumineticsCore™.
